VIVUS — Investor Presentation (January 2017)
37 slides from VIVUS's investor presentation, Jan 10, 2017
Slide 1: Forward looking statement
Forward looking statement This presentation contains "forward-looking" statements that involve risks and uncertainties. These statements typically may be identified by the use of forward-looking words or phrases such as "may," "believe," "expect," "forecast," "intend," "anticipate," "predict," "shou
Slide 2: Forward looking statement (continued)
Forward looking statement risks and uncertainties related to the timing, strategy, tactics and success of the launches and commercialization of STENDRA® (avanafil) or SPEDRA™ (avanafil) by our sublicensees; our ability to successfully complete on acceptable terms, and on a timely basis, avanafil par
Slide 3: Vivus products and product candidate
Vivus products and product candidate Qsymia (phentermine and topiramate extended-release) capsules CIV Treatment for chronic weight management for obese adult patients or overweight adult patients with one weight-related comorbidity Approved by the FDA in July 2012 Commercialized by VIVUS in the U.S
Slide 4: VIVUS recent Accomplishments
VIVUS recent Accomplishments Initiated business strategy review to reshape VIVUS’ business model Received $70 million for a license to commercialize STENDRA in the U.S., Canada, South America, and India In-licensed worldwide development and commercial rights for tacrolimus for the treatment of pulmo
Slide 5: VIVUS Priorities – 2017
VIVUS Priorities –2017 Advance tacrolimus development, including the development of a proprietary formulation of tacrolimus Continue to efficiently monetize Qsymia in the U.S. and seek to monetize Qsymia and Avanafil outside of the U.S. Defend our Qsymia intellectual property rights for Qsymia Advan
Slide 6: Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension ©2017 VIVUS Inc. All rights reserved www.vivus.com 6
Slide 7: Pulmonary arterial hypertension (PAH): Clinical Overview
Pulmonary arterial hypertension (PAH): Clinical Overview ©2017 VIVUS Inc. All rights reserved www.vivus.com 7 Progressive narrowing in pulmonary arteries leading to right heart failure Unmet need with no cure
Slide 8: WHO functional classes for PAH
WHO functional classes For PAH ©2017 VIVUS Inc. All rights reserved www.vivus.com 8 Class I No symptoms with ordinary physical activity Class II Some symptoms with ordinary activity and slight limitation of physical activity Class III Symptoms with less than ordinary activity and increased limitatio
Slide 9: Current treatments
©2017 VIVUS Inc. All rights reserved www.vivus.com 9 Current treatments
Slide 10: Current treatments
Current treatments Type of Treatment MOA Currently Available Medications Medications In Development Endothelin receptor antagonists (ERAs) Inhibit vasoconstrictive effects of endothelin Tracleer (bosentan) Opsumit (macitentan) Letairis (ambrisentan) Ambrisentan / tadalafil combination Phosphodiester
Slide 11: Tacrolimus: Targeting proliferation
Tacrolimus: Targeting proliferation Bone Morphogenic Protein receptor 2 (BMPR2) signaling inhibits vascular smooth muscle proliferation Reduced BMPR2 expression, including loss-of-function mutations in BMPR2, is prevalent in PAH patients, and may contribute to smooth muscle proliferation Phase 1 stu
Slide 12: Tacrolimus Experience in PAH patients
Tacrolimus Experience in PAH patients (StanFOrd) Phase 2a study Randomized, double-blind study 23 WHO class 1-2 patients titrated to target blood levels All target blood levels well tolerated No drug related SAEs, nephrotoxicity or incident diabetes GI complaints (nausea, diarrhea) may provide usefu
Slide 13: Compassionate Use Study: Symptoms and clinical parameters
Compassionate Use Study: Symptoms and clinical parameters ©2017 VIVUS Inc. All rights reserved www.vivus.com 13 Outcomes Treatment ongoing for >50 months Scleroderma patient, at 30-36 months, developed progressive respiratory failure & died Treatment ongoing for >50 months
Slide 14: Tacrolimus/PAH IP status
TACROLIMUS/PAH IP status US and foreign applications pending Filing date is April 30, 2012 so patent term to April 30, 2032 US patent allowed Issued as US9474745 on Oct. 25, 2016 Continuation filed 8 claims EP, AU, CA, and JP are filed 14 ©2017 VIVUS Inc. All rights reserved www.vivus.com
Slide 15: $4.5 Billion growth market - Worldwide (2015)
$4.5 Billion growth market - Worldwide (2015) 15 U.S. market estimated at $2.7B ©2017 VIVUS Inc. All rights reserved www.vivus.com 2015 ($M) 0.2 0.3 0.3 0.6 0.7 1.3 0.1 0.5 0.6 0.1 NA
Slide 16: PAH Opportunity
PAH Opportunity PAH is a serious, rare, and progressive disease Progressive narrowing in pulmonary arteries Resulting in right heart failure and ultimately death Median life expectancy: 5 years from diagnosis (~45 years old, class III/IV) Unmet need Existing drug therapies ONLY target symptoms and s
Slide 17: Avanafil
AVANAFIL 17 ©2017 VIVUS Inc. All rights reserved www.vivus.com
Slide 18: Stendra Prescribing information
Stendra Prescribing information About STENDRA™ STENDRA is a prescription medicine used to treat erectile dysfunction (ED). STENDRA (avanafil) is licensed from Mitsubishi Tanabe Pharma Corporation. VIVUS has development and commercial rights to STENDRA for the treatment of sexual dysfunction worldwid
Slide 19: Avanafil
Avanafil Only erectile dysfunction treatment with a clinically proven 15 minute onset-of-action Able to be taken with food and alcohol Strong safety profile ©2017 VIVUS Inc. All rights reserved www.vivus.com 19
Slide 20: Menarini partnership
Menarini partnership Signed in July 2013 40 Countries in Europe + AUS/NZ As of December 2016, SPEDRA available in 30 countries in the Menarini territories Additional launches expected in 2017 Upfront and potential milestone payments of 71M Euros 41M Euros earned to date Flat royalty on net sales ©20
Slide 21: Metuchen Partnership
Metuchen Partnership Signed in September 2016 United States, Canada, South America, and India Upfront payment of $70M Product sold through Mist Pharmaceuticals Metuchen is responsible for obtaining and maintaining regulatory approvals in its territory ©2017 VIVUS Inc. All rights reserved www.vivus.c
Slide 22: Sanofi partnership
Sanofi partnership Signed in December 2013 Africa, Middle East, Turkey, CIS countries Upfront and potential milestone payments of $61M $5M earned to date Tiered royalty on net sales Sanofi is responsible for obtaining and maintaining regulatory approvals in its territory ©2017 VIVUS Inc. All rights
Slide 23: ANDA/paragraph IV certification
ANDA/paragraph iv certification ANDA Filer: Hetero USA, Inc. Paragraph IV certifications for Orange Book listed patents Notice received on June 20, 2016 VIVUS filed a patent infringement lawsuit on July 27, 2016 on the basis of Hetero’s ANDA submission Lawsuit settled in January 2017 – Hetero grante
Slide 24: Qsymia
Qsymia 24 ©2017 VIVUS Inc. All rights reserved www.vivus.com
Slide 25: About Qsymia
About Qsymia Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related med
Slide 26: Qsymia Summary
QSYMIA Summary Qsymia is a safe and effective therapy for chronic weight management Proprietary extended-release formulation combining low doses of active ingredients from two previously approved compounds, phentermine and topiramate Marketed in the U.S. utilizing a dedicated in-house sales force co
Slide 27: Qsymia magnitude of effect
Qsymia magnitude of effect Pivotal 1-Year Studies: Weight Loss Over Time (Observed/ITT Data) ©2017 VIVUS Inc. All rights reserved www.vivus.com 27 Study 1 (EQUIP1) Study 2 (CONQUER2) Time (Week) Time (Week) 56 ITT-LOCF 56 ITT-LOCF All observed data; *p<0.0001 vs placebo; ‡p<0.0001 vs. Qsymia Mid or
Slide 28: Beneficial effects of weight loss with Qsymia
BENEFICIAL EFFECTS of WEIGHT LOSS WITH Qsymia ©2017 VIVUS Inc. All rights reserved www.vivus.com 28 Diastolic BP Systolic BP Fibrinogen Triglycerides TChol:HDL IWQOL total Fasting glucose HOMA-IR Fasting insulin HbA1c hs-CRP ALT Apnea Hypopnea Index Placebo subtracted effect size Placebo subtracted
Slide 29: Branded anti-obesity market vs. prior year
Sep’16: Branded Market shows a decrease of (-15%) vs. Sep’15 Qsymia (-20%); Belviq (-35%); Contrave (-16%) Source: Jan-2011 through Sep-2013 AO Market based on IMS NPA, Oct-2013 through present AO Market based on IMS Xponent. MAT (000) AO Market TRxs Branded AO TRx Sep-2014 9,029 1,136 Sep-2015 10,1
Slide 30: Qsymia TRxs by Specialty – 2015
Qsymia trxs by Specialty – 2015 Endo is top specialty by productivity Source: VIVUS Data on file- 1/23/2016 file. Data includes MO+PR Retail. 30 Specialty CARD ENDO NP/PA OB/GYN PCP SURG OTHERS Avg Rx/MD 15.5 43.6 10.6 15.9 14.3 12.2 7.0 ©2017 VIVUS Inc. All rights reserved www.vivus.com CARD 1% END
Slide 31: Qsymia CVOT update
Qsymia CVOT update Status of ongoing FDA discussions CVOT remains a post-marketing requirement (PMR) FDA requested potential new timeline to fulfil CVOT PMR FDA needs new data to consider any modification of CVOT PMR Company’s position: There has been no indication throughout Qsymia clinical develop
Slide 32: Patents extend Qsymia coverage to 2029
patents extend qsymia coverage to 2029 Additional VIVUS patents issued with claims covering QSYMIA and extending patent coverage by nine years U.S. Patent No. 8,580,298 issued in 2013 Dosage form claims Continuations 8,895,058 and 9,011,905 issued in 2014 and 2015 U.S. Patent No. 8,580,299 issued in
Slide 33: ANDA/paragraph IV certification
ANDA/paragraph iv certification ANDA Filers: Teva; Dr. Reddy’s Paragraph IV certifications for 10 of 11 Orange Book listed patents 1st Notice received From TEVA (via Actavis) on 07-May-2014 From Dr. Reddy’s (via TEVA) on 05-March-2015 Received favorable Markman ruling Adopted VIVUS’ proposed constru
Slide 34: Financial Summary
Financial Summary 34 ©2017 VIVUS Inc. All rights reserved www.vivus.com
Slide 35: Financial Summary
Financial Summary Company Name: VIVUS, Inc. Ticker: VVUS (NASDAQ Global Market) Share Price: $1.27 (1/5/2017) Market Capitalization: $133 million (1/5/2017) Cash and investments: $283.6 million (9/30/2016) Debt principal balance: $284.6 million (9/30/2016) ©2017 VIVUS Inc. All rights reserved www.vi
Slide 36: Innovative Therapies Novel Products
Innovative Therapies Novel Products Corporate Update January 2017
Slide 37: Innovative Therapies Novel Products
INNOVATIVE THERAPIES Vivus ° NOVEL PRODUCTS Qsymia ~ (phentermine and topiramate Corporate Update extended-release) capsules @ January 2017 STENDRA = (avanafil) tablets af